Future research should focus on screening sensitive cancer types and exploring biomarkers that predict CDK4/6 inhibitor efficacy in more large-scale prospective clinical trials as well as exploring the combination therapy of CDK4/6 inhibitors and immune checkpoint inhibitors for the precise treatment of malignancies. This evidence concerns the gene CDK4 and cancer.